

CORPORATE PRESENTATION

MIT EmTech Spain •

Nuubo provides a new proven and protected product platform for remote patient monitoring

Wireless Dynamic ECG

Biomedical information anywhere and anytime





WEARABLE MEDICAL

NUUBO - HIGH GROWTH POTENTIAL WITH CONTROLLED RISKS



Based on a proven and protected proprietary product platform and technology	Offers solutions in the largest health and medicine segment: <i>Cardiology</i>
IP protection (several international patent applications) CE mark approval (medical device)	Prevention and diagnosis Cardiac rehabilitation
Solutions involve both existing and new markets, reducing impact of adoption risk	3-business model pillars with different weight depending on the market segment
Medical device market Wireless health & wellness Platform (cloud-computing) and remote diagnosis services	Initial sales (wireless medical device + SW Licensing) Recurring sales (biomedical e-textile) Recurring services (prevention, diagnosis, therapies & CR)
Already generating revenues with new- generation wearable medical single-lead ECG solution	Experienced team of 20+ industry experts in collaboration with top-tier research centers and universities in Europe
	Corporate and Scientific Advisory Board including cardiologists and market specialists

PROPRIETARY PRODUCT PLATFORM (biomedical e-textile)





BlendFix[®] Sensor Electrode Technology

- Proprietary patent pending biomedical e-textile technology (wearable sensor)
- Cost-effective, continuous and **noninvasive**
- Excellent ECG signal quality and dynamic control
- Extremely easy-to-use (low physician involvement) with minimal impact on patient lifestyle
- Optimizes key resources (facilities and practitioners) and decreases healthcare provider cost



∩ECG[®] shirt L1 active





PROPRIETARY PRODUCT PLATFORM (wireless sensor device)



· ふ

•0

••



∩ECG[™]minder L1



Technical specifications

ECG

Channels: *single-lead (2 electrodes)* Sampling rate: *250 sps* Bandwidth: *0.05-100 Hz* Class: *IIa* Type: *CF*

Bluetooth[®] v2.0+EDR Class I (250 m) Accelerometer 3-axis HR transmitter (5.5 khz) Data storage 2GB 54 gr

Wearable bioelectronics system

- Wireless dynamic ECG can be used in **real-time** and **holter** modes
- For both individuals and large numbers of patients (multi-user)
- Long-duration: recording can be extended up to a month with a 45-minute daily recharge
- ECG in environments with high levels of physical activity, such as sports
- Can be integrated in numerous use cases (i.e. outpatient, remote monitoring, etc.)



PROPRIETARY PRODUCT PLATFORM (software analysis system)





CLINICALLY PROVEN. BACKED BY SEVERAL CLINICAL STUDIES



Cardiocore

Building clinical evidence is a key component of our initiative to improve patient lifestyle with patient-friendly wearable wireless solutions



Contents lists available at SciVerse ScienceDirect International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard



www.elsevier.es/cardiocore

Cardiocore

Letter to the Editor

New generation dynamic, wireless and remote cardiac monitorization platform: A feasibility study

Leopoldo Perez de Isla ^{a,*}, Vera Lennie ^a, Maribel Quezada ^a, Juan Guinea ^a, Cristina Arce ^a, Pilar Abad ^a, Adriana Saltijeral ^b, Nellys Carolina Campos ^a, Jacobo Crespo ^c, Borja Gonzálvez ^c, Agustín Macia ^b, Jose Zamorano ^d

^a Unidad de Imagen Cardiológica, Hospital Carlos III, Madrid, Spain ^b Cardiología, Hospital del Tajo, Aranjuez, Madrid, Spain ^c Nuubo, Madrid, Spain

^d Unidad de Imagen Cardiovascular, Hospital Clínico San Carlos, Madrid, Spain

"Thus, Nuubo's dynamic ECG is able to obtain similar results to conventional treadmill system during exercise test and allows to obtain echocardiographic images but in an easier and more comfortable manner"



"This new system simplifies the cumbersome traditional methods of connecting electrodes for the user. It also avoids these electrodes from being changed by sweating or sudden movement during exercise, reducing it to the simple act of wearing the garment.

The signal quality has been very good with an average (4, 46), the amplitude of the EKG record in (4.15) and noise signal was rarely detected, or having to check the device (1, 15)"



Nuubo has received *CE Mark* approval for the commercial sale of its new-generation *wearable single-lead ECG solution*; this product complies with the *Medical Device Directive 93/42/EEC*

The company achieved ISO 13485 (Medical Device) and ISO 9001 certifications

The roadmap includes a multi-lead ECG solution, starting the FDA 510(k) clearance process by the beginning of 2012






One in every four Americans suffer from cardiovascular disease, equaling 57 million people SRC: Bluzzele.com - N. Sandhyarani	2.2 million US citizens are estimated to suffer from atrial fibrillation SRC: American Heart Association
Over 6 million reimbursed codes related to Holter monitoring in the US in 2010 SRC: Industry Expert	Sudden cardiovascular death events occur most commonly during or just after physical exertion SRC: Circulation. American Heart Association
Yearly cost of cardiovascular diseases in the US over \$316.000 million SRC: American Heart Association	6.2 million annual hospital discharges diagnosed with cardiovascular disease SRC: USA 2006. NHDS/NCHS and NHLBI

PROVIDING ACCESS TO EXTRAORDINARY MARKET OPPORTUNITIES



Current innovation (i.e.: *iRhythm, Corventis* ...) focused on extending recording length, but with limited diagnostic capability




ANALYSTS ESTIMATE \$MULTI-BN CURRENT AND FUTURE MARKETS



Existing worldwide Holter device, event recorders and telemonitoring market 2010 (\$ million)

Future wearable wireless sensors market predicted to grow to more than 400 million devices annually by 2014



Source: Global Cardiac Monitoring Devices Market 2009-2015 (Axis Research Mind) | ABI Research. "Wearable Wireless Sensors". 2009

NUUBO'S ANNUAL TOTAL ADDRESSABLE SIZE OF PRIORITY MARKETS





Source: NUUBO ANALYSIS ESTIMATES A TOTAL ADDRESSABLE MARKET SIZE OF OVER \$1.7bn FOR KEY 5 EU COUNTRIES + USA

CORPORATE PRESENTATION

NUUBO'S SOLUTIONS PORTFOLIO FOR PRIORITY MARKETS



3 Groups of solutions that address existing and new markets

ORTS MEDICINE	INDIVIDUAL SPORTS (consumer) LIFESTYLE & WELLNESS HIGH RISK PATIENTS
ICOPE STUDY	
	CARDIAC REHABILITATION (Phase III)
r	OLTER & EVENT MONITORING rdiac arrhythmias, AF NCOPE STUDY RDIAC REHABILITATION base II)

INITIAL SALE	Wireless device + SW licensing	49%
RECURRING SALES	Biomedical e-textile (shirts)	50%
RECURRING SERVICES	Remote diagnosis services	1%

with

COMMERCIAL INITIATIVES VALIDATED BY PILOTS & CLINICAL TRIALS



USP PALMAPLANAS



USP Palmaplanas monitors the

players of Mallorca with a

biomedical shirt.

Sudden Death, NUUBO JUL 14 | DE

Unit Arrhythmias and syncope Palmaplanas USP has monitored in real time to players during training Mallorca today thanks to a shirt that captures biomedical electrocardiogram (ECG) through integrated textile electrodes in the garment.

This technology is the first time it is used to analyze the heart of the players in the first group of Mallorca. Throughout the preseason stage of submitting to these tests will be different team members.

Here the test photos with players of Mallorca:

SANITAS - REAL MADRID

Press Releases

Controlled in real time the status of the heart while engaging in physical exercise

Sanitas Medical Services-Real Madrid tested the effectiveness of a shirt that helps you detect and prevent heart disease

• It allows to understand the behavior of the heart, so simple and noninvasive, situations and periods of time so far not possible

Significantly complement all tests currently being made to minimize cases of sudden death in football

• Former first team players such as Zidane, Butragueño or de la Red have already tested it.

Madrid, August 30, 2011

When practicing an intense sporting activity, the athlete's heart behaves very differently than it does when it is at rest. It is therefore important to know and control your heart rate at the time of physical exercise. To this end, Sanita Bedical Services-Real Madrid agt testing an innovative control technology for cardiac dubbed nECG Platform. The main novelty of this technology is the integration into a shirt of a new generation of textile sensors (BlendFix@ Sensor Electrode Technology) developed and patented by the Spanish company Nuubo.

TV news clips describing Nuubo's initiatives:

<u>La Sexta Noticias</u>

Canal Sur Noticias

IB3 Noticias

LEADERSHIP TEAM





Agustín Macià, Founder & CTO

15+ years of experience in entrepreneurship, executive management and development of innovative technology products in global markets. Co-founder of Sip25 (Internet company) and awarded as *"Young Entrepreneur in the Community of Madrid 1998"*. For 7 years acted as *Internet Product Manager* at ONO - the top cable carrier in Spain



Luis Sánchez

Executive Partner & Administration Director and CFO ADAMS *CFO* for seven years, beginning his professional career in financial planning at MAPFRE



Jacobo Crespo

Executive Partner & Corporate Sales and Business Development Director Over a decade of experience in the tech-industry working for companies such as SYBARI Software (a Microsoft company) and RIM (BlackBerry) as *Sales & Business Development Manager*

SCIENTIFIC ADVISORY BOARD





Josep Brugada, MD, PhD, FESC

Cardiologist and Medical Director at Hospital Clinic (Barcelona, Spain) Past President of the *European Heart Rhythm Association* (EHRA) Deputy editor of the *European Heart Journal* Discovered a cause of sudden death syndrome, called *"Brugada Syndrome"*



Rafael Rodríguez de Sanabria, MD

Cardiologist AVS/UPV Associate Professor at Polytechnic University of Valencia (Spain) and Researcher at *i3BH* of UPV Honorific president of INVASCOR (Valencia, Spain) Member of European Society of Cardiology



Javier Saíz, PhD

Professor of Electronic Technology at *Polytechnic University of Valencia* (Spain) Coordinator of *GBIO/i3BH* of *UPV* (Spain) Director of the Masters Program for Biomedical Engineering of *UPV* (Spain)

COMPANY HIGHLIGHTS & MILESTONES





- R&D and Product Development since 2008 IP Protection (patent pending technology) Clinical Science (research, articles & trials) Product CE mark approval ISO13485 and ISO9001 certifications Corporate and Scientific Advisory Board Head Office (Madrid) Nuubo LAB (UPV-Valencia) Clinical LAB (HUVM- Sevilla) Manufacturing facilities (Paiporta-Valencia)
- Nuubo's Team (19)
- (1) Product Manager
- (1) Project Manager
- (3) Product Development Engineers
- (1) Senior Mechanical Engineer
- (4) Software Developers
- (1) Innovation Designer
- (3) Operations & Quality
- (3) Sales & Marketing
- (2) Administration





